

Supplementary Methods

Eligibility Criteria

Inclusion criteria

- a) Meet ACR/SLICC 2012 criteria for SLE
- b) Musculoskeletal symptoms deemed by the investigator to represent active SLE (patients need not have clinical synovitis but must have evidence to support inflammatory cause of symptoms (e.g. morning stiffness, raised inflammatory markers and no more likely alternative diagnosis for these symptoms such as osteoarthritis)
- c) Planned treatment with intramuscular glucocorticoids (this is typically expected to be 120mg Depomedrone as the most commonly used preparation and dose, but clinicians may choose to use an alternative preparation or dose that they consider equivalent for that patient)

Exclusion criteria

- a) Positive blood test for CCP (ever)
- b) Receiving an NSAID within 3 days prior to the intended baseline US date
- c) Receiving daily oral glucocorticoid greater than prednisolone 5mg (or equivalent), or have received IV/IM glucocorticoid in the past 3 months
- d) Received rituximab or cyclophosphamide in the past 6 months
- e) New or increased dose oral immunosuppressant therapy in the past 3 months (methotrexate, mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, cyclophosphamide, intravenous immunoglobulin, belimumab or other regular biologic therapy)

Clinical Assessment

Clinical assessments were performed by a trained assessor blinded to ultrasound status and patient-reported outcomes. These included tender joint count (68 joints), swollen joint count (66 joints), physician musculoskeletal disease activity visual analogue scale (VAS; 0-100mm), physician global assessment VAS (0-100mm), BILAG-2004[1], SLEDAI-2K[2]. Local diagnostic laboratories were used to measure full blood count, liver function tests, urea and electrolytes, anti-nuclear antibodies ANA (including subspecificities), immunoglobulin titres, complement C3 and C4, erythrocyte sedimentation rate and C-reactive protein, urine analysis. At baseline, physicians were also asked to report which clinical inflammatory features were present (morning stiffness, distribution, symmetry, swelling, serology, other lupus features, prior therapy response, Jaccoud's arthropathy or other). They also recorded any other musculoskeletal disorders. For fibromyalgia, we did not apply fibromyalgia diagnostic criteria or assessments of tenderness because an essential criterion of the 2010 ACR criteria is that patients do not have another disorder that could explain the symptoms, and all of our patients were deemed to have active musculoskeletal SLE[3]. We therefore asked physicians to give their overall opinion on whether there was concurrent fibromyalgia and also to document their reasons for this assessment (including fatigue, waking unrefreshed, cognitive symptoms, somatic symptoms, or other). Osteoarthritis (OA) features were documented based

on the ACR criteria for hand osteoarthritis (excluding joint swelling components), deformity and radiographic features (i.e. hard tissue enlargement of 2 or more joints, hard tissue enlargement of DIPs, deformities consistent with OA, previous radiographic evidence in symptomatic sites, or other).

Patient reported outcomes

Patients were blinded to both clinical assessment and ultrasound findings and reported visual analogue scales for general health, musculoskeletal disease activity, musculoskeletal pain, fatigue, morning stiffness (all 0-100mm). They also reported morning stiffness duration, HAQ-DI[4], LupusQoL[5] and L-QoL[6]. Patients also completed a 15 point Likert scale for response to steroid (ranging from -7 to +7) which was used in the first phase analysis. Patient acceptable symptom state as collected. Patients were asked "Think about all the ways your joints, muscles and/or tendons have affected you during the last 48 hours. If your joints, muscles and/or tendons were to remain the next few months as you were during the last 48 hours, would this be acceptable or unacceptable to you?".

Ultrasound assessment

Ultrasound assessments were performed by a trained sonographer blinded to the clinical assessment and patient-reported outcomes. It included both hands and wrists including radiocarpal (RCJ), inter-carpal (ICJ), ulno-carpal(UCJ), 2nd to 5th metacarpophalangeal (MCP) joints, 2nd to 5th proximal interphalangeal (PIP) joints and extensor carpi ulnaris (ECU), extensor wrist tendons (EWT) (1st-5th compartments) and 2nd to 5th flexor digitorum tendons (FDT) in all visits. Ultrasound frequency was in the range of 12-18 MHz and multilinear probe was used. PD was assessed with the highest gain level without background noise, pulse repetition frequency of 750-1000 Hz (depend on the machine use musculoskeletal settings for small joint examination) and medium wall filter.

Each joint was assessed for GS and PD. Each tendon was assessed for GS and PD tenosynovitis. The GS and PD were scored using the OMERACT definitions and semi-quantitative 0–3 scale. GS scoring was: 0 = no synovial hypertrophy, 1 = mild hypertrophy, 2 = moderate hypertrophy and 3 = severe hypertrophy. PD scoring was: 0 = absence of signal, no intra-articular flow; 1 = mild hyperaemia, one or two vessels signal (including one confluent vessel); 2 = moderate hyperaemia, (>grade 1) and <50% of the GS area; 3 = marked hyperaemia, vessels signal in more than half of the synovial area. Tenosynovitis was defined according to the OMERACT criteria and the GS and PD signal scored using semi-quantitative 0–3 scale system (0 = normal, 1 = mild, 2 = moderate and 3 = severe).

Patient and public involvement

Initial development of the research question took place at a meeting involving patients with lupus, patients with other RMDs, partners and family members, and members of Lupus UK. Previous work in lupus arthritis was presented [7-10]. The identification of lupus patients who may be under-treated for their arthritis and the development of better tools for clinical trials were agreed as overall objectives. The USEFUL study was designed to answer these questions. PPI partners were involved in the decisions about the study visits and assessments, including detailed work on the detail and burden of patient-reported outcomes. The benefit of feeding back results of scans and blood tests to participants was emphasized. Although this is not possible during the study (because of blinding and scientific integrity), we

incorporated feedback at the week 6 visit. A key aspect of our design was that primary endpoint selection was predicated on a patient-reported outcome. This ensured that our results would guide treatment in a way that was relevant to patients. A grant proposal was submitted to LupusUK and lay review was included in that assessment. A detailed protocol, patient information sheet and patient reported outcomes CRF were designed and reviewed and modified by a PPI partner to ensure readability and ease of completion. During the study, a trial steering committee included two patient members. This work included review of study progress and recruitment strategy. For dissemination, a lay summary of the study concept, design and results has been prepared working with one of the patient members of the TSC. This will be submitted to the LupusUK *News and Views* magazine.

Pilot phase analysis and selection of primary endpoint

The primary objective was to test the hypothesis that clinical response would be better in patients with abnormal ultrasound. Because the change in clinical variables, or the most responsive clinical variable, was not previously known, we chose a 2-phase design with internal pilot. We required accurate estimates of the change in each of the clinical variables at the group level, and of the proportion of patients with active US (GS ≥ 2 and/or PD ≥ 1) present at baseline (estimated 60% from previous work)[10]. Recent recommendations for pilot and feasibility studies recommend that if a binary outcome is to be estimated, a sample size of 60 is the best trade-off between maximising the accuracy of the estimate and minimising the number of patients included. Required sample sizes for the estimation of Kendall's tau-a to within a confidence interval of ± 0.15 are $n=35$ to $n=70$, assuming the value is between 0.2 and 0.6 (plausible values for the associations between the clinical variables and the patient-reported change in their symptoms) thus performing the interim analysis in the first $n=70$ for phase 1 will be sufficient to meet both objectives. We therefore performed a blinded analysis of clinical data in the first 70 patients. Longitudinal ultrasound data were not analysed in this phase. The rate of ultrasound activity (presence of any joint scoring GS ≥ 2 and/or PD ≥ 1) at baseline was calculated at the group level. Changes in each of the candidate primary outcomes was correlated with the Likert scores for response to therapy at both 2 and 6 weeks. The candidate outcome with the strongest association was selected as the primary outcome; the visit at which the strongest association is identified was selected as the primary endpoint. The baseline mean and follow-up standard deviation of the chosen outcome calculated in all patients was used to calculate a revised sample size, taking into account the estimated rate of ultrasound activity.

EMS VAS at week 2 was the most strongly correlated with patient-reported change in pain. At $\alpha=0.05$, $1-\text{Beta}=0.8$ we required 130 patients in total to show a difference of 20% of the baseline value in EMS VAS at 2 weeks between those with active US in at least one joint and those without active US (allowing for 10% dropout).

Analysis of baseline data

Within categories of the musculoskeletal domains of the existing instruments (SLEDAI-2K-MSK score 0 or 4; BILAG (2004) (MSK-BILAG) A, B, C, D/E) each of the following musculoskeletal-specific variables were summarized at baseline: tender joint count (68 joints), swollen joint count (66 joints), patient's painful joint count,

patient pain VAS, patient musculoskeletal disease activity VAS, physician musculoskeletal disease activity VAS, health assessment questionnaire disability index (HAQ-DI), severity of early morning stiffness VAS, duration of early morning stiffness, total scores for ultrasound grey scale, power Doppler and tenosynovitis and ultrasound-detected presence of osteophytes in the hands and wrists.

The following non-specific outcomes were summarised at baseline within categories of the musculoskeletal domains of the existing instruments (SLEDAI-2K-MSK score 0 or 4; BILAG (2004) merged ABC vs DE), further split by the categories of any other domains found to be involved in at least 12 patients (a minimum usually stipulated for accurate estimation of a quantity in pilot studies): physician's global VAS, patient fatigue VAS, erythrocyte sedimentation rate (ESR), Ig titres, complement titres.

Internal pilot phase analysis and identification of primary efficacy variable

The pilot phase analysis included the first 70 patients. Patient Likert scale responses to the question “Since you have been given treatment has your joint and muscle pain been...” generally indicated improvement and are shown in Figure S1.

Of the candidate primary outcomes, at both week 2 and 6, EMS VAS was the most strongly correlated with patient-reported change in pain (Kendall’s Tau=0.291, Table S). The correlation was strongest at week 2. This was also the case for EMS (mins) and patient-reported painful joint count; for the remaining variables, stronger associations were found at week 6 than week 2. The primary endpoint for the main trial was therefore defined as EMS VAS (mm) at 2 weeks; EMS VAS at 6 weeks, and the remaining candidate variables at both 2 and 6 weeks, were deemed secondary endpoints. At alpha=0.05, 1-beta=0.8 we required 130 patients in total to show a difference of 20% of the baseline value in the primary endpoint between those with active US in at least one joint and those without active US.

Table S1: Kendall's tau-a correlations with patient-reported change in pain

Variable	W2	W6
TJC68	-0.036	0.154
SJC66	-0.070	0.125
Physician MSK Disease Activity VAS	0.049	0.117
SLEDAI MSK	0.053	0.157
BILAG MSK	0.021	0.150
HAQ-DI	0.062	0.124
Patient MSK Disease Activity VAS	0.117	0.153
MSK Pain VAS	0.232	0.088
EMS VAS	0.291	0.159
EMS mins	0.279	0.070
Painful Joint Count	0.135	0.147

Table S2: Baseline MSK-specific SLE characteristics

Population: Full analysis set.

All values reported as median (IQR), range, except for BILAG MSK and SLEDAI MSK which are reported as n/N (%).

	All patients	US activity at baseline		
		Inactive	Active	
	N=133	N=55	N=78	
EMS VAS (mm)	73.0 (57.0, 87.0), 0.0 to 100.0	67.0 (48.0, 83.0), 2.0 to 99.0	75.5 (63.0, 92.0), 0.0 to 100.0	z=-2.55, p=0.011
EMS duration (mins)	90.0 (30.0, 120.0), 0.0 to 600.0	70.0 (30.0, 120.0), 0.0 to 360.0	90.0 (30.0, 150.0), 0.0 to 600.0	z=-1.02, p=0.306
Tender 68 joint count	17.0 (7.0, 28.0), 0.0 to 68.0	15.0 (4.0, 27.0), 0.0 to 68.0	19.0 (10.0, 31.0), 0.0 to 68.0	z=-2.21, p=0.027
Swollen 66 joint count	1.0 (0.0, 4.0), 0.0 to 32.0	0.0 (0.0, 0.0), 0.0 to 10.0	3.0 (1.0, 6.0), 0.0 to 32.0	z=-6.52, p<0.001
Patient painful joint count	16.0 (9.0, 28.0), 0.0 to 42.0	11.0 (7.0, 20.0), 0.0 to 40.0	22.0 (14.0, 32.0), 1.0 to 42.0	z=-3.84, p<0.001
Physician MSK Disease Activity VAS (mm)	33.0 (21.0, 49.0), 0.0 to 90.0	24.0 (15.0, 36.0), 0.0 to 75.0	39.5 (30.0, 55.0), 13.0 to 90.0	z=-4.86, p<0.001
HAQ-DI score	1.4 (0.6, 2.0), 0.0 to 3.0	1.4 (0.3, 1.8), 0.0 to 2.8	1.4 (0.8, 2.1), 0.0 to 3.0	z=-1.82, p=0.069
Patient MSK disease activity VAS (mm)	65.0 (32.0, 79.0), 2.0 to 95.0	54.0 (28.0, 75.0), 7.0 to 92.0	70.5 (37.0, 81.0), 2.0 to 95.0	z=-1.87, p=0.061
MSK pain VAS (mm)	63.0 (47.0, 74.0), 5.0 to 99.0	57.0 (34.0, 69.0), 10.0 to 93.0	67.5 (53.0, 75.0), 5.0 to 99.0	z=-2.72, p=0.007
Total grey scale (joints)	5.0 (2.0, 9.0), 0.0 to 49.0	1.0 (0.0, 4.0), 0.0 to 10.0	7.0 (5.0, 11.0), 2.0 to 49.0	z=-7.67, p<0.001
Total power Doppler (joints)	0.0 (0.0, 1.0), 0.0 to 34.0	0.0 (0.0, 0.0), 0.0 to 0.0	0.0 (0.0, 2.0), 0.0 to 34.0	z=-6.00, p<0.001
Total osteophyte (joints)	0.0 (0.0, 0.0), 0.0 to 19.0	0.0 (0.0, 1.0), 0.0 to 8.0	0.0 (0.0, 0.0), 0.0 to 19.0	z=0.88, p=0.379
Total erosion score (joints)	0.0 (0.0, 0.0), 0.0 to 44.0	0.0 (0.0, 0.0), 0.0 to 1.0	0.0 (0.0, 0.0), 0.0 to 44.0	z=-1.86, p=0.063
Total OMERACT/EULAR GSPD score (joints)	5.0 (2.0, 9.0), 0.0 to 49.0	1.0 (0.0, 4.0), 0.0 to 10.0	7.0 (5.0, 11.0), 2.0 to 49.0	z=-7.67, p<0.001

USEFUL Study I: Musculoskeletal ultrasound identifies patients with lupus arthritis with better response to therapy: Supplementary material

	All patients		US activity at baseline		
			Inactive	Active	
	N=133		N=55	N=78	
Total amended OMERACT/EULAR GSPD score (joints)	4.0 (1.0, 7.0), 0.0 to 36.0		1.0 (0.0, 4.0), 0.0 to 10.0	6.0 (4.0, 9.0), 1.0 to 36.0	z=-6.51, p<0.001
Total grey scale (tendons)	0.0 (0.0, 1.0), 0.0 to 21.0		0.0 (0.0, 0.0), 0.0 to 7.0	0.0 (0.0, 2.0), 0.0 to 21.0	z=-3.52, p<0.001
Total power Doppler (tendons)	0.0 (0.0, 0.0), 0.0 to 20.0		0.0 (0.0, 0.0), 0.0 to 6.0	0.0 (0.0, 1.0), 0.0 to 20.0	z=-3.74, p<0.001
Total OMERACT/EULAR GSPD score (tendons)	0.0 (0.0, 1.0), 0.0 to 21.0		0.0 (0.0, 0.0), 0.0 to 8.0	0.0 (0.0, 2.0), 0.0 to 21.0	z=-3.51, p<0.001
Total amended OMERACT/EULAR GSPD score (tendons)	0.0 (0.0, 1.0), 0.0 to 20.0		0.0 (0.0, 0.0), 0.0 to 7.0	0.0 (0.0, 1.0), 0.0 to 20.0	z=-3.47, p=0.001
BILAG MSK score					
D/E	2/133 (2)		2/55 (4)	0/78 (0)	chisq=26.54, p<0.001
C	65/133 (49)		40/55 (73)	25/78 (32)	
B	52/133 (39)		10/55 (18)	42/78 (54)	
A	14/133 (11)		3/55 (5)	11/78 (14)	
SLEDAI MSK domain score					
0	55/133 (41)		36/55 (65)	19/78 (24)	chisq=22.46, p<0.001
4	78/133 (59)		19/55 (35)	59/78 (76)	

EMS-VAS, tender joint count, swollen joint count, painful joint count, physician MSK VAS, and the MSK-BILAG and MSK-SLEDAI-2K were all significantly worse in patients with ultrasound synovitis (all p<0.05). EMS duration was not significantly different between ultrasound groups (Table S1).

Table S3: Baseline global SLE characteristics

Population: Full analysis set

All values reported as median (IQR), range.

	All patients	US activity at baseline		
		Inactive	Active	
	N=133	N=55	N=78	
Physician global VAS (mm)	34.0 (20.0, 51.0), 2.0 to 80.0	27.0 (15.0, 41.0), 2.0 to 77.0	41.0 (26.0, 56.0), 5.0 to 80.0	z=-3.59, p<0.001
General health VAS (mm)	59.0 (46.0, 73.0), 4.0 to 97.0	52.0 (42.0, 71.0), 4.0 to 96.0	62.5 (47.0, 78.0), 7.0 to 97.0	z=-1.77, p=0.076
Abnormal fatigue VAS (mm)	79.0 (61.0, 90.0), 0.0 to 100.0	75.0 (60.0, 86.0), 3.0 to 100.0	83.5 (65.0, 90.0), 0.0 to 100.0	z=-1.62, p=0.105
BILAG total score	9.0 (2.0, 10.0), 0.0 to 26.0	2.0 (1.0, 10.0), 0.0 to 26.0	9.0 (8.0, 13.0), 1.0 to 26.0	z=-3.38, p=0.001
SLEDAI total score	6.0 (2.0, 7.0), 0.0 to 16.0	4.0 (2.0, 6.0), 0.0 to 12.0	6.0 (4.0, 8.0), 0.0 to 16.0	z=-3.04, p=0.002
L-QoL score	17.0 (9.0, 21.0), 0.0 to 25.0, n=132	15.0 (8.0, 20.0), 0.0 to 25.0, n=55	17.0 (10.0, 21.0), 0.0 to 25.0, n=77	z=-0.90, p=0.370
LUPUSQOL: Physical health	40.6 (18.8, 65.6), 0.0 to 100.0	43.8 (21.9, 68.8), 0.0 to 100.0	37.5 (15.6, 59.4), 0.0 to 100.0	z=0.83, p=0.405
LUPUSQOL: Pain	33.3 (16.7, 66.7), 0.0 to 100.0	50.0 (16.7, 66.7), 0.0 to 91.7	33.3 (16.7, 58.3), 0.0 to 100.0	z=1.36, p=0.173
LUPUSQOL: Planning	41.7 (16.7, 75.0), 0.0 to 100.0	50.0 (8.3, 75.0), 0.0 to 100.0	41.7 (25.0, 83.3), 0.0 to 100.0	z=-0.10, p=0.921
LUPUSQOL: Intimate relationship	25.0 (0.0, 75.0), 0.0 to 100.0, n=109	31.3 (0.0, 75.0), 0.0 to 100.0, n=50	25.0 (0.0, 75.0), 0.0 to 100.0, n=59	z=-0.26, p=0.792
LUPUSQOL: Burden to others	25.0 (8.3, 66.7), 0.0 to 100.0	25.0 (8.3, 62.5), 0.0 to 100.0	25.0 (0.0, 66.7), 0.0 to 100.0	z=-0.10, p=0.923
LUPUSQOL: Emotional health	50.0 (29.2, 75.0), 0.0 to 100.0	54.2 (33.3, 75.0), 0.0 to 100.0	47.9 (29.2, 75.0), 0.0 to 100.0	z=1.08, p=0.279

USEFUL Study I: Musculoskeletal ultrasound identifies patients with lupus arthritis with better response to therapy: Supplementary material

	All patients	US activity at baseline		
		Inactive	Active	
LUPUSQOL: Body image	50.0 (25.0, 83.3), 0.0 to 100.0, n=115	62.5 (25.0, 83.3), 0.0 to 100.0, n=47	45.0 (25.0, 75.6), 0.0 to 100.0, n=68	z=1.20, p=0.229
LUPUSQOL: Fatigue	25.0 (12.5, 50.0), 0.0 to 100.0	31.3 (6.3, 43.8), 0.0 to 81.3	25.0 (12.5, 50.0), 0.0 to 100.0	z=0.34, p=0.734

Table S4: Baseline SLE laboratory tests

Population: Full analysis set

All values reported as median (IQR), range, except for antibody status, reported as n/N (%).

	All patients	US activity at baseline		
		Inactive	Active	
	N=133	N=55	N=78	
Erythrocyte sedimentation rate (mm/hr)	13.9 (5.3, 26.7), 1.8 to 115.6	11.0 (5.3, 19.3), 1.8 to 69.3	17.1 (6.4, 34.2), 2.1 to 115.6	z=-2.21, p=0.027
C-reactive protein (mg/L)	4.0 (4.0, 7.1), 1.0 to 50.0	4.0 (4.0, 5.6), 1.0 to 35.0	4.0 (4.0, 9.0), 1.0 to 50.0	z=-1.72, p=0.086
C3 (g/l)	1.3 (1.1, 1.4), 0.1 to 2.2	1.2 (1.1, 1.4), 0.1 to 2.0	1.3 (1.1, 1.5), 0.8 to 2.2	z=-0.56, p=0.579
C4 (g/l)	0.2 (0.2, 0.3), 0.1 to 0.8	0.2 (0.2, 0.3), 0.1 to 0.8	0.2 (0.2, 0.3), 0.1 to 0.6	z=0.64, p=0.524
IgG titre (g/l)	12.8 (10.3, 15.7), 1.8 to 37.0, n=132	11.3 (9.2, 15.3), 1.8 to 33.6, n=55	13.2 (11.8, 17.6), 4.1 to 37.0, n=77	z=-3.07, p=0.002
IgA titre (g/l)	2.5 (2.0, 3.3), 0.8 to 16.7, n=131	2.6 (1.9, 3.3), 0.8 to 7.0, n=55	2.4 (2.0, 3.4), 0.9 to 16.7, n=76	z=0.27, p=0.790
IgM titre (g/l)	0.9 (0.6, 1.4), 0.1 to 8.3, n=131	0.8 (0.5, 1.3), 0.1 to 2.0, n=55	1.0 (0.6, 1.5), 0.2 to 8.3, n=76	z=-1.93, p=0.053
ANA antibody				
Currently negative	8/133 (6)	3/55 (5)	5/78 (6)	chisq=0.05, p=0.819
Currently positive	125/133 (94)	52/55 (95)	73/78 (94)	
Ro antibody				
Currently negative	75/133 (56)	28/55 (51)	47/78 (60)	chisq=1.15, p=0.284
Currently positive	58/133 (44)	27/55 (49)	31/78 (40)	
La antibody				

USEFUL Study I: Musculoskeletal ultrasound identifies patients with lupus arthritis with better response to therapy: Supplementary material

	All patients	US activity at baseline		
		Inactive	Active	
Currently negative	109/133 (82)	44/55 (80)	65/78 (83)	chisq=0.24, p=0.623
Currently positive	24/133 (18)	11/55 (20)	13/78 (17)	
Sm antibody				
Currently negative	107/133 (80)	49/55 (89)	58/78 (74)	chisq=4.45, p=0.035
Currently positive	26/133 (20)	6/55 (11)	20/78 (26)	
RNP antibody				
Currently negative	111/133 (83)	50/55 (91)	61/78 (78)	chisq=3.77, p=0.052
Currently positive	22/133 (17)	5/55 (9)	17/78 (22)	
Anti-cardiolipin antibody				
Currently negative	119/132 (90)	49/54 (91)	70/78 (90)	chisq=0.04, p=0.850
Currently positive	13/132 (10)	5/54 (9)	8/78 (10)	
Anti-B2 glycoprotein antibody				
Currently negative	119/129 (92)	48/52 (92)	71/77 (92)	chisq=0.00, p=0.983
Currently positive	10/129 (8)	4/52 (8)	6/77 (8)	

Acute phase markers and lupus serology were associated with ultrasound findings. Median (IQR) ESR was 17.1 (2.1,115.6) in patients with ultrasound synovitis and 11.0 (5.3, 19.3) in patients with normal ultrasound (p=0.027). Also, consistent with our previous report [11], total serum IgG was associated with ultrasound synovitis. Normal range for IgG was 6.0 to 16.0 mg/L. Median (IQR) IgG was 13.2 (11.8, 17.6) in patients with ultrasound synovitis and 11.3 (9.2, 15.3) in patients with normal ultrasound (p=0.002). CRP did not differ by US activity status; most CRP values were normal, and this biomarker would therefore be unlikely to be clinically useful. Median (IQR) CRP was 4.0 (4.0, 9.0) in patients with ultrasound synovitis and 4.0 (4.0, 5.6) in patients with normal ultrasound (p=0.086). Ultrasound synovitis was also associated with Sm and RNP antibodies (Table S3).

Table S5: Baseline BILAG comparison

Population: Full analysis set

All values reported as median (IQR), range, unless otherwise stated. US activity is defined as GS>=2 and/or PD>0 in at least 1 joint.

	All patients	BILAG MSK score		
		C	B	A
	N=133	N=67	N=52	N=14
EMS VAS (mm)	73.0 (57.0, 87.0), 0.0 to 100.0	67.0 (49.0, 83.0), 3.0 to 99.0	75.0 (63.0, 89.0), 0.0 to 100.0	93.5 (66.0, 96.0), 21.0 to 100.0
EMS duration (mins)	90.0 (30.0, 120.0), 0.0 to 600.0	60.0 (30.0, 120.0), 0.0 to 360.0	90.0 (30.0, 135.0), 0.0 to 360.0	112.5 (90.0, 300.0), 30.0 to 600.0
Tender 68 joint count	17.0 (7.0, 28.0), 0.0 to 68.0	10.0 (4.0, 21.0), 0.0 to 61.0	20.5 (11.0, 32.0), 0.0 to 68.0	26.5 (21.0, 32.0), 8.0 to 68.0
Swollen 66 joint count	1.0 (0.0, 4.0), 0.0 to 32.0	0.0 (0.0, 0.0), 0.0 to 16.0	2.5 (1.0, 4.5), 0.0 to 16.0	8.0 (5.0, 16.0), 0.0 to 32.0
Patient painful joint count	16.0 (9.0, 28.0), 0.0 to 42.0	12.0 (7.0, 23.0), 0.0 to 42.0	20.0 (14.0, 32.0), 1.0 to 42.0	27.0 (18.0, 40.0), 8.0 to 42.0
Physician MSK Disease Activity VAS (mm)	33.0 (21.0, 49.0), 0.0 to 90.0	26.0 (17.0, 36.0), 0.0 to 75.0	38.5 (29.5, 51.0), 14.0 to 77.0	65.5 (54.0, 68.0), 3.0 to 90.0
HAQ-DI score	1.4 (0.6, 2.0), 0.0 to 3.0	1.0 (0.3, 1.6), 0.0 to 2.8	1.5 (0.8, 2.1), 0.0 to 3.0	1.6 (1.3, 2.6), 0.8 to 2.9
Patient MSK disease activity VAS (mm)	65.0 (32.0, 79.0), 2.0 to 95.0	54.0 (29.0, 77.0), 2.0 to 92.0	68.0 (31.5, 78.5), 2.0 to 95.0	76.0 (68.0, 89.0), 2.0 to 95.0
MSK pain VAS (mm)	63.0 (47.0, 74.0), 5.0 to 99.0	51.0 (33.0, 68.0), 5.0 to 90.0	69.0 (59.0, 75.0), 10.0 to 99.0	74.5 (68.0, 93.0), 57.0 to 99.0
Total grey scale (joints)	5.0 (2.0, 9.0), 0.0 to 49.0	4.0 (0.0, 6.0), 0.0 to 17.0	7.0 (4.0, 9.5), 0.0 to 30.0	11.0 (2.0, 30.0), 0.0 to 49.0

USEFUL Study I: Musculoskeletal ultrasound identifies patients with lupus arthritis with better response to therapy: Supplementary material

	All patients	BILAG MSK score		
		C	B	A
	N=133	N=67	N=52	N=14
Total power Doppler (joints)	0.0 (0.0, 1.0), 0.0 to 34.0	0.0 (0.0, 0.0), 0.0 to 3.0	0.0 (0.0, 1.0), 0.0 to 10.0	1.5 (1.0, 9.0), 0.0 to 34.0
Total osteophyte (joints)	0.0 (0.0, 0.0), 0.0 to 19.0	0.0 (0.0, 0.0), 0.0 to 4.0	0.0 (0.0, 1.0), 0.0 to 19.0	0.0 (0.0, 3.0), 0.0 to 9.0
US activity in joints at baseline, n/N (%)				
Inactive	55/133 (41)	42/67 (63)	10/52 (19)	3/14 (21)
Active	78/133 (59)	25/67 (37)	42/52 (81)	11/14 (79)
Total grey scale (tendons)	0.0 (0.0, 1.0), 0.0 to 21.0	0.0 (0.0, 0.0), 0.0 to 5.0	0.0 (0.0, 2.0), 0.0 to 9.0	0.0 (0.0, 2.0), 0.0 to 21.0
Total power Doppler (tendons)	0.0 (0.0, 0.0), 0.0 to 20.0	0.0 (0.0, 0.0), 0.0 to 2.0	0.0 (0.0, 0.5), 0.0 to 6.0	0.0 (0.0, 1.0), 0.0 to 20.0

Table S6: Baseline SLEDAI comparison

Population: Full analysis set

All values reported as median (IQR), range, unless otherwise stated. US activity is defined as GS>=2 and/or PD>0 in at least 1 joint.

	All patients	SLEDAI MSK domain score	
		0	4
	N=133	N=55	N=78
EMS VAS (mm)	73.0 (57.0, 87.0), 0.0 to 100.0	67.0 (46.0, 83.0), 0.0 to 99.0	76.5 (63.0, 90.0), 11.0 to 100.0
EMS duration (mins)	90.0 (30.0, 120.0), 0.0 to 600.0	60.0 (30.0, 120.0), 0.0 to 360.0	90.0 (30.0, 150.0), 0.0 to 600.0
Tender 68 joint count	17.0 (7.0, 28.0), 0.0 to 68.0	10.0 (4.0, 26.0), 0.0 to 47.0	20.5 (10.0, 32.0), 0.0 to 68.0
Swollen 66 joint count	1.0 (0.0, 4.0), 0.0 to 32.0	0.0 (0.0, 1.0), 0.0 to 8.0	3.0 (1.0, 7.0), 0.0 to 32.0
Patient painful joint count	16.0 (9.0, 28.0), 0.0 to 42.0	12.0 (7.0, 20.0), 0.0 to 40.0	22.5 (14.0, 34.0), 1.0 to 42.0
Physician MSK Disease Activity VAS (mm)	33.0 (21.0, 49.0), 0.0 to 90.0	26.0 (16.0, 33.0), 0.0 to 58.0	41.5 (27.0, 56.0), 3.0 to 90.0
HAQ-DI score	1.4 (0.6, 2.0), 0.0 to 3.0	1.0 (0.3, 1.5), 0.0 to 2.3	1.5 (0.9, 2.1), 0.0 to 3.0
Patient MSK disease activity VAS (mm)	65.0 (32.0, 79.0), 2.0 to 95.0	62.0 (36.0, 75.0), 7.0 to 95.0	69.0 (29.0, 81.0), 2.0 to 95.0
MSK pain VAS (mm)	63.0 (47.0, 74.0), 5.0 to 99.0	52.0 (34.0, 71.0), 5.0 to 94.0	68.0 (55.0, 75.0), 10.0 to 99.0
Total grey scale (joints)	5.0 (2.0, 9.0), 0.0 to 49.0	2.0 (0.0, 5.0), 0.0 to 12.0	7.0 (5.0, 10.0), 0.0 to 49.0
Total power Doppler (joints)	0.0 (0.0, 1.0), 0.0 to 34.0	0.0 (0.0, 0.0), 0.0 to 1.0	0.0 (0.0, 2.0), 0.0 to 34.0
Total osteophyte (joints)	0.0 (0.0, 0.0), 0.0 to 19.0	0.0 (0.0, 0.0), 0.0 to 5.0	0.0 (0.0, 0.0), 0.0 to 19.0
US activity in joints at baseline, n/N (%)			

USEFUL Study I: Musculoskeletal ultrasound identifies patients with lupus arthritis with better response to therapy: Supplementary material

	All patients	SLEDAI MSK domain score	
Inactive	55/133 (41)	36/55 (65)	19/78 (24)
Active	78/133 (59)	19/55 (35)	59/78 (76)
Total grey scale (tendons)	0.0 (0.0, 1.0), 0.0 to 21.0	0.0 (0.0, 0.0), 0.0 to 5.0	0.0 (0.0, 1.0), 0.0 to 21.0
Total power Doppler (tendons)	0.0 (0.0, 0.0), 0.0 to 20.0	0.0 (0.0, 0.0), 0.0 to 2.0	0.0 (0.0, 0.0), 0.0 to 20.0

Figure S1: Likert Scale responses





Table S7: Primary endpoint EMS-VAS at week 2

Population	US activity at baseline		Difference between medians (95% CI)		
	Inactive median (SE)	Active median (SE)	Unadjusted	Adjusted primary*, P value	Adjusted sensitivity**, P value
Full Analysis Set (FAS)	57.75 (4.09)	58.60 (5.86)	0.85 (-7.06, 8.76)	-7.70 (-18.92, 3.52), p=0.178	-6.31 (-18.10, 5.49), p=0.293
Per Protocol (PP)	58.00 (3.97)	59.00 (5.75)	1.00 (-4.88, 6.88)	-7.51 (-17.13, 2.11), p=0.126	-6.30 (-16.83, 4.24), p=0.241
FAS: No fibromyalgia	56.30 (4.53)	51.40 (6.01)	-4.90 (-15.36, 5.56)	-12.08 (-24.11, -0.06), p=0.049	-12.82 (-22.20, -3.44), p=0.007
PP: No fibromyalgia	57.00 (3.24)	50.00 (6.87)	-7.00 (-20.16, 6.16)	-12.30 (-22.76, -1.85), p=0.021	-14.78 (-20.75, -8.80), p<0.001

*Adjusted for baseline EMS-VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale

Table S8: Secondary Clinical Outcomes at 2 weeks

Variable	US activity at baseline		Difference between medians (95% CI)		
	Inactive median (SE)	Active median (SE)	Unadjusted	Adjusted primary*, P value	Adjusted sensitivity**, P value
Tender 68 joint count	4.90 (0.79)	10.95 (1.65)	6.05 (2.74, 9.36)	-0.57 (-2.31, 1.17), p=0.521	-0.66 (-2.31, 0.99), p=0.427
Swollen 66 joint count	-0.00 (0.67)	1.00 (0.96)	1.00 (0.18, 1.82)	0.00 (-0.67, 0.67), p=0.995	0.00 (-0.67, 0.67), p=0.995
Patient painful joint count	6.50 (0.99)	14.50 (1.76)	8.00 (4.87, 11.13)	-0.93 (-4.44, 2.58), p=0.602	-0.76 (-4.49, 2.96), p=0.686
Physician MSK DA VAS (mm)	12.75 (1.79)	25.40 (2.47)	12.65 (7.85, 17.45)	7.07 (1.38, 12.77), p=0.015	7.08 (2.61, 11.55), p=0.002
HAQ-DI	1.16 (0.20)	1.32 (0.16)	0.16 (-0.18, 0.50)	0.01 (-0.05, 0.07), p=0.681	0.01 (-0.06, 0.09), p=0.746
Patient MSK DA VAS (mm)	48.45 (2.75)	48.10 (3.04)	-0.35 (-8.23, 7.53)	-1.58 (-10.11, 6.95), p=0.715	-4.16 (-13.73, 5.42), p=0.391
Patient MSK Pain VAS (mm)	41.95 (5.16)	54.20 (2.51)	12.25 (3.61, 20.89)	2.48 (-7.55, 12.50), p=0.627	1.05 (-10.94, 13.04), p=0.864
EMS (mins)	60.00 (17.87)	60.50 (11.75)	0.50 (-24.04, 25.04)	-4.16 (-19.44, 11.12), p=0.594	0.13 (-10.82, 11.09), p=0.981
Total GSPD (joints)	-0.00 (0.52)	3.95 (1.32)	3.95 (2.09, 5.81)	0.25 (-1.60, 2.09), p=0.793	0.25 (-1.60, 2.09), p=0.793
Total GSPD (tendons)>0	-0.00 (0.14)	2.80 (1.24)	2.80 (0.50, 5.10)	1.96 (0.88, 3.04), p=0.001	1.79 (-0.11, 3.68), p=0.064
Physician's global VAS (mm)	15.60 (1.96)	26.65 (1.67)	11.05 (6.27, 15.83)	6.99 (2.55, 11.43), p=0.003	7.02 (2.71, 11.33), p=0.002
Patient general health VAS (mm)	49.70 (2.54)	54.10 (5.16)	4.40 (-4.80, 13.60)	2.19 (-10.02, 14.40), p=0.725	0.92 (-10.52, 12.36), p=0.874
Abnormal fatigue VAS (mm)	64.80 (2.50)	71.45 (1.59)	6.65 (1.02, 12.28)	-0.38 (-6.14, 5.38), p=0.897	-0.87 (-7.08, 5.35), p=0.784

Population: Full Analysis Set. Due to low numbers of patients scoring >0, groups were compared at the 90th percentile instead of the median for total GSPD (tendons).

*Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale

Table S9: Secondary Clinical Outcomes at 6 weeks

Variable	US activity at baseline		Difference between medians (95% CI)		
	Inactive median (SE)	Active median (SE)	Unadjusted	Adjusted primary*, P value	Adjusted sensitivity**, P value
Tender 68 joint count	6.90 (2.01)	12.55 (2.34)	5.65 (-0.15, 11.45)	-0.17 (-3.20, 2.86), p=0.913	0.03 (-2.80, 2.86), p=0.985
Swollen 66 joint count	3.45 (1.72)	6.55 (1.84)	3.10 (-0.58, 6.78)	1.04 (-3.96, 6.04), p=0.682	0.80 (-2.15, 3.75), p=0.586
Patient painful joint count	8.15 (1.98)	13.10 (1.89)	4.95 (0.67, 9.23)	-2.54 (-5.71, 0.62), p=0.115	-1.80 (-4.83, 1.22), p=0.242
Physician MSK DA VAS (mm)	10.90 (1.69)	27.15 (4.72)	16.25 (7.41, 25.09)	3.43 (-3.37, 10.24), p=0.317	4.19 (-3.15, 11.54), p=0.257
HAQ-DI	0.97 (0.24)	1.29 (0.17)	0.33 (-0.14, 0.79)	-0.04 (-0.23, 0.15), p=0.665	-0.01 (-0.13, 0.10), p=0.836
Patient MSK DA VAS (mm)	52.55 (4.24)	46.05 (4.61)	-6.50 (-20.50, 7.50)	-5.75 (-18.85, 7.34), p=0.385	-3.83 (-15.76, 8.10), p=0.527
Patient MSK Pain VAS (mm)	55.05 (3.45)	61.75 (3.61)	6.70 (-3.74, 17.14)	2.12 (-6.07, 10.31), p=0.611	1.98 (-6.30, 10.26), p=0.638
EMS VAS (mm)	60.15 (3.65)	66.30 (3.39)	6.15 (-2.07, 14.37)	-0.34 (-7.96, 7.27), p=0.928	-2.71 (-9.87, 4.44), p=0.450
EMS (mins)	42.25 (11.50)	86.00 (18.36)	43.75 (13.59, 73.91)	6.92 (-8.20, 22.03), p=0.365	8.81 (-9.37, 26.99), p=0.338
Total GSPD (joints)	-0.00 (0.60)	4.30 (1.82)	4.30 (1.53, 7.07)	0.29 (-2.82, 3.41), p=0.853	0.39 (-2.41, 3.18), p=0.786
Total GSPD (tendons)	1.80 (0.55)	6.45 (1.58)	4.65 (1.46, 7.84)	3.75 (-0.39, 7.89), p=0.076	3.42 (0.41, 6.42), p=0.026
Physician's global VAS (mm)	13.85 (2.75)	28.00 (4.83)	14.15 (2.21, 26.09)	4.63 (-3.36, 12.63), p=0.249	4.31 (-3.56, 12.18), p=0.277
Patient general health VAS (mm)	58.25 (3.11)	52.20 (2.93)	-6.05 (-14.13, 2.03)	-3.00 (-9.35, 3.34), p=0.352	-5.85 (-17.93, 6.22), p=0.342
Abnormal fatigue VAS (mm)	68.10 (3.95)	73.70 (4.86)	5.60 (-6.82, 18.02)	-0.85 (-14.41, 12.70), p=0.899	-0.71 (-15.60, 14.19), p=0.925

Population: Full Analysis Set. Due to low numbers of patients scoring >0, groups were compared at the 90th percentile instead of the median for SJC66 and at the 96th percentile for total GSPD

(tendons). *Adjusted for baseline EMS VAS **Also adjusted for immunosuppressant and oral steroid use. EMS=Early morning stiffness; VAS=Visual analogue scale

Table S10: Simple comparison of changes at 2 weeks (in all patients)

Variable	Change by US activity at baseline		Difference between medians (95% CI)
	Inactive median (SE)	Active median (SE)	Unadjusted
EMS VAS	-6.30 (4.05)	-18.65 (5.18)	-12.35 (-19.85, -4.85), p=0.001
Tender 68 joint count	-3.05 (0.95)	-5.90 (0.81)	-2.85 (-4.43, -1.27), p<0.001
Swollen 66 joint count	0.00 (0.87)	-1.05 (1.32)	-1.05 (-2.47, 0.37), p=0.147
Patient painful joint count	-2.40 (1.17)	-4.35 (1.32)	-1.95 (-5.39, 1.49), p=0.261
Physician MSK DA VAS (mm)	-8.85 (1.62)	-16.65 (2.06)	-7.80 (-11.90, -3.70), p<0.001
HAQ-DI	-0.01 (0.19)	-0.13 (0.08)	-0.12 (-0.39, 0.15), p=0.390
Patient MSK DA VAS (mm)	-5.95 (2.53)	-13.95 (4.23)	-8.00 (-19.51, 3.51), p=0.173
Patient MSK Pain VAS (mm)	-6.35 (2.50)	-10.40 (2.41)	-4.05 (-10.60, 2.50), p=0.225
EMS (mins)	0.00 (16.54)	-9.25 (3.87)	-9.25 (-45.25, 26.75), p=0.614
Total GSPD (joints)	0.00 (1.60)	-3.10 (0.89)	-3.10 (-6.07, -0.13), p=0.041
Total GSPD (tendons)	-0.00 (0.16)	1.10 (0.61)	1.10 (-0.03, 2.23), p=0.057
Physician's global VAS (mm)	-9.70 (2.15)	-12.10 (1.55)	-2.40 (-6.34, 1.54), p=0.231
Total BILAG score	0.00 (1.99)	-1.25 (1.31)	-1.25 (-5.37, 2.87), p=0.551
Total SLEDAI score	0.00 (1.34)	0.00 (1.41)	0.00 (-0.61, 0.61), p=1.000
Patient general health VAS (mm)	-2.85 (2.04)	-4.45 (4.04)	-1.60 (-10.64, 7.44), p=0.728
Abnormal fatigue VAS (mm)	-3.00 (1.13)	-5.20 (2.09)	-2.20 (-7.25, 2.85), p=0.392
L-QoL	0.00 (1.10)	-0.35 (0.90)	-0.35 (-1.93, 1.23), p=0.662

Population: Full Analysis Set. Due to low numbers of patients scoring >0, groups were compared at the 90th percentile instead of the median for total GSPD (tendons). Improvement in SLEDAI MSK was adjusted for total SLEDAI at baseline rather than SLEDAI MSK to prevent perfect prediction (improvement was only possible if SLEDAI MSK=4 at baseline). DA=Disease activity; EMS=Early morning stiffness; GSPD=combined grey scale and power Doppler score; MSK=Musculoskeletal; US=Ultrasound; VAS=Visual analogue scale

Table S11: Simple comparison of changes at 2 weeks (in patients without fibromyalgia)

Variable	Change by US activity at baseline		Difference between medians (95% CI)
	Inactive median (SE)	Active median (SE)	Unadjusted
EMS VAS	-5.10 (4.36)	-19.55 (4.57)	-14.45 (-22.29, -6.61), p<0.001
Tender 68 joint count	-2.70 (1.52)	-6.80 (0.86)	-4.10 (-7.75, -0.45), p=0.028
Swollen 66 joint count	0.00 (0.82)	-1.00 (0.34)	-1.00 (-2.06, 0.06), p=0.065
Patient painful joint count	-2.90 (1.05)	-5.90 (1.47)	-3.00 (-7.06, 1.06), p=0.146
Physician MSK DA VAS (mm)	-8.45 (1.33)	-18.75 (2.07)	-10.30 (-14.72, -5.88), p<0.001
HAQ-DI	0.00 (0.09)	-0.13 (0.06)	-0.13 (-0.22, -0.03), p=0.009
Patient MSK DA VAS (mm)	-9.55 (3.14)	-14.50 (5.78)	-4.95 (-17.44, 7.54), p=0.436
Patient MSK Pain VAS (mm)	-4.05 (3.17)	-12.45 (2.49)	-8.40 (-16.67, -0.13), p=0.047
EMS (mins)	0.00 (18.61)	-10.00 (7.36)	-10.00 (-49.77, 29.77), p=0.622
Total GSPD (joints)	-0.00 (1.34)	-3.15 (0.64)	-3.15 (-6.04, -0.26), p=0.033
Total GSPD (tendons)	-0.00 (0.18)	1.00 (0.13)	1.00 (0.74, 1.26), p<0.001
Physician's global VAS (mm)	-9.70 (1.66)	-15.50 (2.04)	-5.80 (-10.18, -1.42), p=0.010
Total BILAG score	0.00 (1.92)	-3.55 (2.37)	-3.55 (-9.45, 2.35), p=0.232
Total SLEDAI score	0.00 (1.15)	0.00 (1.56)	0.00 (-0.99, 0.99), p=1.000
Patient general health VAS (mm)	1.70 (2.86)	-5.90 (3.48)	-7.60 (-14.21, -0.99), p=0.025
Abnormal fatigue VAS (mm)	-2.20 (1.51)	-5.05 (2.39)	-2.85 (-7.79, 2.09), p=0.258
L-QoL	-0.30 (1.07)	-1.00 (0.53)	-0.70 (-2.29, 0.89), p=0.385

Population: Full Analysis Set (restricted to patients without fibromyalgia, n=101). Due to low numbers of patients scoring >0, groups were compared at the 90th percentile instead of the median for total GSPD (tendons). Improvement in SLEDAI MSK was adjusted for total SLEDAI at baseline rather than SLEDAI MSK to prevent perfect prediction (improvement was only possible if SLEDAI MSK=4 at baseline). DA=Disease activity; EMS=Early morning stiffness; GSPD=combined grey scale and power Doppler score; MSK=Musculoskeletal; US=Ultrasound; VAS=Visual analogue scale

Table S12: Simple comparison of changes at 6 weeks (in all patients)

Variable	Change by US activity at baseline		Difference between medians (95% CI)
	Inactive median (SE)	Active median (SE)	Unadjusted
EMS VAS	-9.25 (3.06)	-10.90 (2.76)	-1.65 (-10.69, 7.39), p=0.720
Tender 68 joint count	-2.05 (1.99)	-4.55 (1.31)	-2.50 (-6.85, 1.85), p=0.260
Swollen 66 joint count	0.00 (0.91)	-1.00 (0.88)	-1.00 (-2.25, 0.25), p=0.117
Patient painful joint count	-1.50 (1.64)	-7.00 (1.33)	-5.50 (-9.68, -1.32), p=0.010
Physician MSK DA VAS (mm)	-9.85 (1.41)	-14.40 (2.39)	-4.55 (-10.36, 1.26), p=0.124
HAQ-DI	0.00 (0.17)	-0.12 (0.07)	-0.12 (-0.37, 0.14), p=0.362
Patient MSK DA VAS (mm)	-4.50 (3.82)	-14.50 (3.05)	-10.00 (-20.49, 0.49), p=0.061
Patient MSK Pain VAS (mm)	-4.15 (2.53)	-6.40 (3.14)	-2.25 (-10.04, 5.54), p=0.567
EMS (mins)	0.00 (22.90)	-1.50 (16.37)	-1.50 (-26.56, 23.56), p=0.907
Total GSPD (joints)	0.00 (1.98)	-3.15 (0.97)	-3.15 (-7.26, 0.96), p=0.133
Total GSPD (tendons)	0.30 (0.74)	2.05 (1.73)	1.75 (-1.44, 4.94), p=0.281
Physician's global VAS (mm)	-8.75 (1.87)	-11.05 (2.53)	-2.30 (-8.71, 4.11), p=0.475
Total BILAG score	-0.05 (2.38)	-1.70 (1.01)	-1.65 (-6.68, 3.38), p=0.520
Total SLEDAI score	-0.60 (1.37)	-1.95 (1.20)	-1.35 (-3.96, 1.26), p=0.311
Patient general health VAS (mm)	-1.90 (2.72)	-5.40 (2.64)	-3.50 (-10.56, 3.56), p=0.331
Abnormal fatigue VAS (mm)	-0.10 (2.75)	-4.45 (2.82)	-4.35 (-11.41, 2.71), p=0.223
LUPUSQoL: Physical health	5.16 (4.79)	-0.63 (2.37)	-5.78 (-14.53, 2.97), p=0.195
LUPUSQoL: Pain	7.92 (3.38)	3.75 (5.57)	-4.17 (-15.57, 7.24), p=0.467
LUPUSQoL: Planning	0.00 (2.43)	0.00 (6.45)	0.00 (-9.27, 9.27), p=1.000
LUPUSQoL: Intimate relationship	0.00 (8.85)	0.00 (10.09)	0.00 (-6.82, 6.82), p=1.000
LUPUSQoL: Burden to others	8.33 (3.67)	-0.00 (4.61)	-8.33 (-15.41, -1.26), p=0.021
LUPUSQoL: Emotional health	0.00 (3.96)	-1.46 (3.24)	-1.46 (-9.52, 6.60), p=0.722
LUPUSQoL: Body image	0.25 (4.12)	-1.29 (4.71)	-1.54 (-10.15, 7.06), p=0.725
LUPUSQoL: Fatigue	0.00 (2.52)	0.00 (3.91)	0.00 (-5.05, 5.05), p=1.000
L-QoL	-0.55 (1.46)	-0.90 (0.72)	-0.35 (-2.71, 2.01), p=0.771
	Change by US activity at baseline		Odds ratio (95% CI)
	Inactive %	Active %	Unadjusted
BILAG MSK improved	32%	51%	2.15 (1.10, 4.17), p=0.024
SLEDAI MSK improved	22%	38%	2.17 (1.41, 3.35), p<0.001

Population: Full Analysis Set. Due to low numbers of patients scoring >0, groups were compared at the 90th percentile instead of the median for total GSPD (tendons). Improvement in SLEDAI MSK was adjusted for total SLEDAI at baseline rather than SLEDAI MSK to prevent perfect prediction (improvement was only possible if SLEDAI MSK=4 at baseline). DA=Disease activity; EMS=Early morning stiffness; GSPD=combined grey scale and power Doppler score; MSK=Musculoskeletal; US=Ultrasound; VAS=Visual analogue scale

Table S13: Simple comparison of changes at 6 weeks (in patients without fibromyalgia)

Variable	Change by US activity at baseline		Difference between medians (95% CI)
	Inactive median (SE)	Active median (SE)	Unadjusted
EMS VAS	-9.90 (3.33)	-9.45 (2.23)	0.45 (-7.08, 7.98), p=0.907
Tender 68 joint count	-2.60 (1.96)	-5.20 (1.23)	-2.60 (-7.35, 2.15), p=0.282
Swollen 66 joint count	0.00 (0.81)	-0.95 (0.35)	-0.95 (-2.44, 0.54), p=0.210
Patient painful joint count	-0.80 (1.81)	-7.35 (1.56)	-6.55 (-10.78, -2.32), p=0.003
Physician MSK DA VAS (mm)	-9.25 (1.98)	-15.60 (2.20)	-6.35 (-13.26, 0.56), p=0.072
HAQ-DI	0.00 (0.15)	-0.11 (0.06)	-0.11 (-0.36, 0.14), p=0.382
Patient MSK DA VAS (mm)	-7.00 (3.39)	-14.60 (3.30)	-7.60 (-17.36, 2.16), p=0.125
Patient MSK Pain VAS (mm)	-2.35 (4.68)	-6.60 (2.64)	-4.25 (-14.33, 5.83), p=0.407
EMS (mins)	0.00 (17.25)	0.00 (9.47)	0.00 (-20.46, 20.46), p=1.000
Total GSPD (joints)	-0.00 (2.06)	-3.40 (0.76)	-3.40 (-7.64, 0.84), p=0.116
Total GSPD (tendons)	1.10 (0.83)	3.80 (1.69)	2.70 (-0.62, 6.02), p=0.111
Physician's global VAS (mm)	-8.60 (2.75)	-14.85 (2.69)	-6.25 (-14.02, 1.52), p=0.113
Total BILAG score	-0.00 (2.67)	-2.75 (0.92)	-2.75 (-8.33, 2.83), p=0.334
Total SLEDAI score	0.00 (1.11)	-1.80 (0.82)	-1.80 (-4.08, 0.48), p=0.121
Patient general health VAS (mm)	-1.45 (2.75)	-4.30 (2.58)	-2.85 (-10.12, 4.42), p=0.442
Abnormal fatigue VAS (mm)	-1.05 (3.79)	-2.85 (2.60)	-1.80 (-10.33, 6.73), p=0.671
LUPUSQoL: Physical health	6.09 (3.61)	-0.94 (2.15)	-7.03 (-15.29, 1.23), p=0.095
LUPUSQoL: Pain	7.92 (3.37)	1.67 (4.03)	-6.25 (-16.00, 3.50), p=0.204
LUPUSQoL: Planning	0.83 (3.37)	-0.00 (3.98)	-0.83 (-8.21, 6.55), p=0.823
LUPUSQoL: Intimate relationship	0.00 (7.56)	0.00 (7.07)	0.00 (-4.93, 4.93), p=1.000
LUPUSQoL: Burden to others	8.33 (1.60)	0.00 (3.25)	-8.33 (-13.70, -2.96), p=0.002
LUPUSQoL: Emotional health	-0.00 (3.88)	0.42 (3.23)	0.42 (-8.17, 9.00), p=0.924
LUPUSQoL: Body image	0.00 (5.98)	-2.17 (4.73)	-2.17 (-12.72, 8.38), p=0.686
LUPUSQoL: Fatigue	0.31 (2.69)	0.00 (3.13)	-0.31 (-5.18, 4.56), p=0.899
L-QoL	-0.45 (1.34)	-0.95 (0.50)	-0.50 (-2.68, 1.68), p=0.652
	Change by US activity at baseline		Odds ratio (95% CI)
	Inactive %	Active %	Unadjusted
BILAG MSK improved	26%	56%	3.74 (2.03, 6.90), p<0.001
SLEDAI MSK improved	15%	37%	3.24 (1.62, 6.50), p=0.001

Population: Full Analysis Set (restricted to patients without fibromyalgia, n=101). Due to low numbers of patients scoring >0, groups were compared at the 95th percentile instead of the median for total GSPD (tendons). Improvement in SLEDAI MSK was adjusted for total SLEDAI at baseline rather than SLEDAI MSK to prevent perfect prediction (improvement was only possible if SLEDAI MSK=4 at baseline). DA=Disease activity; EMS=Early morning stiffness; GSPD=combined grey scale and power Doppler score; MSK=Musculoskeletal; US=Ultrasound; VAS=Visual analogue scale

References for Supplement

1. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford, England)*. 2005 Jul; 44(7):902-906.
2. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *The Journal of rheumatology*. 2002 Feb; 29(2):288-291.
3. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis care & research*. 2010; 62(5):600-610.
4. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. *The Journal of rheumatology*. 1982 Sep-Oct; 9(5):789-793.
5. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. *Arthritis care & research*. 2007; 57(6):972-979.
6. Doward L, McKenna S, Whalley D, Tennant A, Griffiths B, Emery P, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. *Annals of the rheumatic diseases*. 2009; 68(2):196-200.
7. Zayat AS, Md Yusof MY, Wakefield RJ, Conaghan PG, Emery P, Vital EM. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology (Oxford, England)*. 2016 Mar; 55(3):485-494.
8. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythematosus. *Current opinion in rheumatology*. 2017 Sep; 29(5):486-492.
9. Mahmoud K, Zayat AS, Yusof Y, Hensor E, Conaghan PG, Emery P, et al. Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus. *Rheumatology*. 2019.
10. Zayat AS, Mahmoud K, Yusof M, Yuzaiful M, Mukherjee S, D'Agostino M-A, et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. *Rheumatology*. 2018.
11. Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'agostino M-a, Hensor EM, et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. *Rheumatology*. 2018; 58(2):304-312.